113 related articles for article (PubMed ID: 27838511)
1. Non-insulin anti-diabetic drugs: An update on pharmacological interactions.
Ruscica M; Baldessin L; Boccia D; Racagni G; Mitro N
Pharmacol Res; 2017 Jan; 115():14-24. PubMed ID: 27838511
[TBL] [Abstract][Full Text] [Related]
2. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
4. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
[TBL] [Abstract][Full Text] [Related]
7. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
Thompson AM; Linnebur SA; Vande Griend JP; Saseen JJ
Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
[TBL] [Abstract][Full Text] [Related]
8. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
10. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus.
Hussain S; Chowdhury TA
Drugs; 2019 Feb; 79(3):231-242. PubMed ID: 30742277
[TBL] [Abstract][Full Text] [Related]
12. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus.
Brunton SA
Postgrad Med; 2012 Jul; 124(4):74-83. PubMed ID: 22913896
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
[TBL] [Abstract][Full Text] [Related]
15. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Garg SK
Diabetes Technol Ther; 2010 Jan; 12(1):11-24. PubMed ID: 20082581
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
17. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
19. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
20. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
